A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy

NCT07668804 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy Due to Age-Related Macular Degeneration

Interventions

DRUG: TO-O-1007 (low-dose)
DRUG: TO-O-1007 (high-dose)
PROCEDURE: Sham injection

Sponsor

Theratocular Biotek Co.